AstraZeneca and Medicines for Malaria Venture (MMV) announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca's extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease.

Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks.

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results up to 76-weeks from a Phase 3 study of ONGLYZA™ (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naïve adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

Pfizer Inc. (NYSE: PFE) announced the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA).

AstraZeneca and Targacept, Inc., announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

Amgen (Nasdaq: AMGN) announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence.

Findings from an open-label, uncontrolled long-term extension of a Phase 3 registration trial demonstrated efficacy of SIMPONI in patients with moderately to severely active rheumatoid arthritis despite methotrexate therapy at two years.